You're urinating constantly. Here's the biological reason.

FUT2 encodes a fucosyltransferase enzyme that adds protective sugars to the epithelial cells lining your urinary tract. These sugars are antigens that your immune system recognizes as self. They also create a chemical environment that affects which bacteria can colonize your urinary tract epithelium. When FUT2 is working normally, your urinary tract epithelium displays the right antigen signature and creates a selective environment for bacterial colonization.

If you carry the non-secretor variant of FUT2 (rs601338), your urinary tract epithelium doesn’t express these protective antigens properly. Roughly 20% of the population are FUT2 non-secretors. Without proper antigen expression, your urinary tract loses immune recognition and becomes vulnerable to pathogens that would normally be filtered out. Uropathogenic bacteria like E. coli can colonize more easily, triggering inflammation and the sensation of urgency even when infection isn’t present.

You experience this as constant urge to urinate, recurrent UTIs, or a persistent feeling of incomplete emptying. You might have had multiple urine cultures come back negative even though you felt like you had an infection. Your urinary tract is essentially flying blind without the right immune recognition signals.

UMOD encodes uromodulin, a protein secreted in massive quantities by the thick ascending limb of the loop of Henle in your kidneys. Uromodulin lines the urinary tract epithelium and acts as both a physical barrier and an immune agent. It traps uropathogenic bacteria, preventing them from adhering to your epithelial cells. It also modulates your local immune response so that bacteria are cleared without triggering excessive inflammation.

Variants in UMOD reduce the amount of uromodulin your kidneys secrete into your urine. Studies show roughly 10-20% of the population carry these variants. Low uromodulin means your urinary tract loses its primary physical and immunological defense against bacterial adhesion and colonization. Bacteria can attach to your epithelial cells more easily, and your immune response becomes hyperactive because there’s no uromodulin to modulate it.

You feel this as constant urge to urinate, recurrent infections despite negative cultures, and often a sense that something is irritating your bladder even when nothing is growing. You might have had antibiotics prescribed multiple times for symptoms that return as soon as you finish the course.

VDR encodes the vitamin D receptor, a nuclear receptor that activates gene expression when vitamin D binds to it. In your urinary tract, vitamin D signaling triggers the production of antimicrobial peptides, particularly cathelicidin and defensin. These peptides are part of your innate immune system; they directly kill bacteria and modulate inflammatory responses without triggering systemic infection.

Common VDR variants (particularly the FokI polymorphism and Bsm1 polymorphism) reduce the efficiency of vitamin D signaling in your urinary epithelium. Roughly 50-70% of the population carries at least one of these variants. Even if your serum vitamin D level is normal, a VDR variant means your urinary tract cells cannot respond to vitamin D as effectively to mount antimicrobial defenses. Your epithelial cells produce fewer antimicrobial peptides, leaving you vulnerable to bacterial overgrowth.

You experience this as recurrent UTIs, persistent urge to urinate, and often a history of infections that seemed to come out of nowhere despite good hygiene and normal urinalysis results. The infections are real, but your immune response is inadequate because your epithelial cells aren’t producing enough antimicrobial peptides.

MTHFR encodes methylenetetrahydrofolate reductase, an enzyme central to the methylation cycle and nucleotide synthesis. Your urinary epithelial cells require constant nucleotide synthesis to repair DNA damage from immune activation and bacterial exposure. They also need an active methylation cycle to regulate immune gene expression and maintain barrier integrity. MTHFR is the gatekeeper for both processes.

Common MTHFR variants (C677T and A1298C) reduce enzyme activity by 35-70%, depending on which variant you carry. Roughly 30-40% of the population carries at least one C677T variant. Reduced MTHFR activity means your epithelial cells cannot synthesize nucleotides or methylate immune regulators quickly enough to keep up with the demand created by chronic bacterial exposure. Your cells become progressively damaged and inflamed, and your immune tolerance collapses.

You feel this as worsening frequency over time, a sense that your urinary tract is becoming more reactive, and often an inability to tolerate normal dietary triggers (certain foods make urgency worse). Your immune system in the urinary tract is literally running out of the molecular resources needed to maintain homeostasis.

IL6 encodes interleukin-6, a key inflammatory cytokine produced by urinary tract epithelial cells and immune cells in response to bacterial exposure. In normal amounts, IL-6 coordinates a proportionate immune response: bacteria are detected, antimicrobial peptides are produced, bacteria are cleared, inflammation resolves. But IL-6 production is tightly regulated by genetic variants.

Common IL6 promoter variants increase baseline IL-6 production. Roughly 25-30% of the population carries the high-production variants. High IL-6 variants mean your urinary tract mounts an exaggerated inflammatory response to bacteria that would barely register in someone with low-production variants. Your epithelial cells flood the space with inflammatory signals, and your immune response becomes self-perpetuating. You feel the inflammation as urgency and frequency, but blood cultures and urine cultures are often negative because bacterial levels are actually low.

You experience this as symptoms that feel like a UTI but don’t respond to antibiotics, recurrent false positives on urinalysis, and a sense that your urinary tract is in a state of constant low-level alarm. You might have been treated repeatedly for infections that were actually just your immune system overreacting.

TLR4 encodes toll-like receptor 4, a pattern recognition receptor on immune cells and epithelial cells that detects bacterial lipopolysaccharide (LPS), a component of gram-negative bacteria like E. coli. When TLR4 binds LPS, it triggers a cascade of immune signaling that tells your body there’s a bacterial threat. This is essential for clearing real infections. But TLR4 sensitivity is genetically variable.

Common TLR4 variants (particularly Asp299Gly and Thr399Ile) reduce TLR4’s ability to bind LPS. Roughly 5-10% of people carry these variants. But the more common pattern is a genetic background that increases TLR4 signaling efficiency: your TLR4 is hypersensitive, and it triggers immune alarms at bacterial levels that wouldn’t bother most people. A small number of bacteria in your urinary tract triggers a disproportionate TLR4 response, leading to systemic inflammatory signals and the sensation of infection.

You feel this as symptoms that are out of proportion to the bacterial load (urinalysis shows few or no bacteria, but you feel terrible), a sense that you’re always on the edge of infection, and often a history of antibiotics that didn’t actually help because the primary problem wasn’t bacterial overgrowth but immune hypersensitivity.